CN113813285A - 一种祛除脚气足部护理靶向泡足液 - Google Patents
一种祛除脚气足部护理靶向泡足液 Download PDFInfo
- Publication number
- CN113813285A CN113813285A CN202111236658.9A CN202111236658A CN113813285A CN 113813285 A CN113813285 A CN 113813285A CN 202111236658 A CN202111236658 A CN 202111236658A CN 113813285 A CN113813285 A CN 113813285A
- Authority
- CN
- China
- Prior art keywords
- solution
- beriberi
- foot
- small molecular
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010047601 Vitamin B1 deficiency Diseases 0.000 title claims abstract description 40
- 208000002894 beriberi Diseases 0.000 title claims abstract description 40
- 239000007788 liquid Substances 0.000 title claims abstract description 13
- 238000002791 soaking Methods 0.000 title claims abstract description 13
- 230000008685 targeting Effects 0.000 title description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 102000008186 Collagen Human genes 0.000 claims abstract description 31
- 108010035532 Collagen Proteins 0.000 claims abstract description 31
- 229920001436 collagen Polymers 0.000 claims abstract description 31
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims abstract description 30
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims abstract description 26
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000005711 Benzoic acid Substances 0.000 claims abstract description 15
- 235000010233 benzoic acid Nutrition 0.000 claims abstract description 15
- 239000005862 Whey Substances 0.000 claims abstract description 14
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 14
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 14
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 13
- 241000251468 Actinopterygii Species 0.000 claims abstract description 13
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 13
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 13
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004327 boric acid Substances 0.000 claims abstract description 13
- 150000002500 ions Chemical class 0.000 claims abstract description 13
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 13
- 239000011777 magnesium Substances 0.000 claims abstract description 13
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 claims abstract description 13
- 229960001907 nitrofurazone Drugs 0.000 claims abstract description 13
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 13
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 13
- 229920002258 tannic acid Polymers 0.000 claims abstract description 13
- 229940033123 tannic acid Drugs 0.000 claims abstract description 13
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 13
- 241000283690 Bos taurus Species 0.000 claims abstract description 12
- 230000001502 supplementing effect Effects 0.000 claims abstract description 12
- 239000013589 supplement Substances 0.000 claims description 7
- 108010014603 Leukocidins Proteins 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 abstract description 5
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 abstract description 5
- 208000031888 Mycoses Diseases 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 5
- 229910001425 magnesium ion Inorganic materials 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 229920000832 Cutin Polymers 0.000 abstract description 3
- 230000037311 normal skin Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 210000002683 foot Anatomy 0.000 description 21
- 239000010410 layer Substances 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 241000233866 Fungi Species 0.000 description 7
- 230000008439 repair process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 206010048768 Dermatosis Diseases 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011844 Dacryocystitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012871 anti-fungal composition Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000005418 spin wave Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/345—Nitrofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及保健技术领域，具体为一种祛除脚气足部护理靶向泡足液，包括细胞修护溶液和祛脚气溶液,所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁1～3％、鱼胶原蛋白肽1～3％、牛胶原带白肽1～3％、乳清肽1～3％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液；所述祛脚气溶液按照重量百分比配制,由水杨酸0.5～5％、苯甲酸0.5～5％、硼酸0.5～5％、鞣酸0.15～0.5％、间苯二酚0.1～0.5％、呋喃西林0.05～0.15％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液。该发明小分子团活性水、化合物、肽、镁离子协同作用，彻底祛除各种类型的脚气脚臭、去除角质、抑菌修护、保护足部正常的皮肤组织，短时间内从根本上解决真菌感染问题，达到足部健康的目的。
Description
技术领域
本发明涉及保健技术领域，具体为一种祛除脚气足部护理靶向泡足液。
背景技术
脚气即脚癣是由浅部致病真菌感染足部皮肤所引起的一种慢性传染疾病，我国的脚气发病率很高，它也是全球性广泛流行的一种疾病。在气候温暖潮湿的热带亚热带地区尤其高发。我国南方部分地区的发病率达50％-60％，在一些特殊的职业(如矿工等)中，发病率可达80％-100％。有资料显示，一个人在一生中发生足癣的概率超过80％。因此，可以毫不夸张地说，一半的中国人有脚气，特别是成人中脚气的发病率更高。
现有的祛除脚气的办法多为用西药杀菌，但是西药成分杀死表皮层部分真菌，可能灼伤皮肤，有刺激性，破坏角质层，对皮肤有腐蚀性，价格太高，会蜕皮，会使真菌产生耐药性，无法深入真皮层杀菌，含有激素。
发明内容
本发明的目的是提供一种祛除脚气足部护理靶向泡足液。
本发明的上述发明目的是通过以下技术方案得以实现的：
一种祛除脚气足部护理靶向泡足液，包括细胞修护溶液和祛脚气溶液,所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁1～3％、鱼胶原蛋白肽1～3％、牛胶原带白肽1～3％、乳清肽1～3％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液；
所述祛脚气溶液按照重量百分比配制,由水杨酸0.5～5％、苯甲酸0.5～5％、硼酸0.5～5％、鞣酸0.15～0.5％、间苯二酚0.1～0.5％、呋喃西林0.05～0.15％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液。
优选的，所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁1％、鱼胶原蛋白肽1％、牛胶原带白肽1％、乳清肽1％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液；所述祛脚气溶液按照重量百分比配制，由水杨酸0.5％、苯甲酸0.5％、硼酸0.5％、鞣酸0.15％、间苯二酚0.1％、呋喃西林0.05％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液。
优选的，所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁3％、鱼胶原蛋白肽3％、牛胶原带白肽3％、乳清肽3％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液；所述祛脚气溶液按照重量百分比配制，由水杨酸5％、苯甲酸5％、硼酸5％、鞣酸0.5％、间苯二酚0.5％、呋喃西林0.15％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液；
优选的，所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁2％、鱼胶原蛋白肽2％、牛胶原带白肽2％、乳清肽2％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液；所述祛脚气溶液按照重量百分比配制,由水杨酸3％、苯甲酸3％、硼酸3％、鞣酸3％、间苯二酚0.3％、呋喃西林0.1％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液。
本发明所用的原料及功效如下：
小分子团活性水：先将水净化，去除杂质，激活为人体能快速吸收的小分子团水，并将溶存氧降低，将远红外线极大化的负离子水，由于低渗透压，能快速吸收，在-10℃～-15℃度是不结冰的、长效定型三年状态下水分子不重合，核磁共振检测呈半幅宽、有一种独特的自旋波，含有红外线，是非常洁净的小分子团活性水；
海洋深层离子镁：镁离子作为多种酶的激活剂，参与300多余种酶促反应，富含大量“镁”离子，能有效促进肌肤新陈代谢，使皮肤细胞活性化，促进保湿成分神经酰胺(Ceramide)生成，同时有助于排除造成皮肤各种色斑的最大主因——黑色素沉着而提亮肤色；
鱼胶原蛋白肽：可细分为：大分子胶原蛋白和小分子胶原蛋白肽，平常我们食用猪蹄的胶质，里面含有胶原蛋白，但是它是大分子蛋白质，其分子量在30万道尔顿以上，并不能被人体直接吸收，并且吸收率很低，而通过酸碱、酶切等技术把分子量控制在6000道尔顿以内的胶原蛋白，称之为胶原蛋白肽，肽是介于氨基酸和大分子蛋白质之间的物质，两个或以上的氨基酸脱水缩合形成若干个肽键从而组成一个肽，多个肽进行多级折叠就组成一个蛋白质分子，肽是精准的蛋白质片段，其分子只有纳米般大小，胃肠、血管及肌肤等极易吸收，其吸收率要远远高于大分子蛋白质；
乳清肽：高溶解,易吸收，乳清肽是小分子肽,纯度高,溶解快,溶解透明无杂质,易吸收、无蛋白变性，增强免疫，乳清肽具有免疫增强作用和抗肿瘤作用,能促进机体产生抗体,能增强肿瘤病人免疫功能，促代谢，缓疲劳，乳清肽能明显提高血红细胞供氧能力，有利于提高有氧代谢，增强代谢过程，保持神经应激，乳清肽可以保持中枢神经系统良好的应激状态,可有效缓解脑力疲劳，美白去毒，乳清肽具有抗毒、解毒、防止黑色素沉淀、促进松果腺再生；
水杨酸：除防腐杀菌作用外，还有祛除汗臭、止痒消肿、止痛消炎等功能；
苯甲酸：仅0.1％浓度的苯甲酸可抑制细菌生长，改变pH值对苯甲酸盐的杀菌作用和抑菌作用影响很大，在碱性介质中其效果明显降低，pH值在2.5～4.5时效果最佳；
硼酸：用于杀菌剂、消毒剂、收敛剂和防腐剂，对多种细菌、霉菌均有抑制作用。作用原理是它能与细菌蛋白质中的氨基结合而发挥作用，可用于皮肤、粘膜、伤口、口腔、阴道、膀胱等冲洗消毒，也可用于耳炎、烧伤、烫伤、湿疹；
鞣酸：主要作用为收敛剂，能沉淀蛋白质，与生物碱、甙及重金属等均能形成不溶性复合物，主要用于局部，其11％～20％软膏用于渗出性溃疡、烫伤、褥疮、痔疮、湿疹；
间苯二酚：临床上能够起到很好的杀霉菌作用，能够有效的改善霉菌性的皮肤病，在医药上外用治湿疹、牛皮癣等皮肤病；
呋喃西林：一种用作消毒防腐药的有机化合物，分子式为C6H6N4O4在临床上用于治疗创伤、烧伤、化脓性皮炎、中耳炎、泪囊炎、阴道炎、膀胱冲洗、褥疮；
综上所述，本发明的有益技术效果为：
1.该发明从脚的角质层的表层到皮肤表皮的基底层的清除真菌，渗透到真皮层能真正清除真菌，只清除真菌感染层，修复被感染的皮肤，保护皮肤正常组织，消杀与修护同时进行，小分子团活性水、化合物、肽、镁离子协同作用，彻底祛除各种类型的脚气脚臭、去除角质、抑菌修护、保护足部正常的皮肤组织，短时间内从根本上解决真菌感染问题，达到足部健康的目的。
具体实施方式
以下结合实施例对本发明作进一步详细说明。
实施例1
本发明公开的一种祛除脚气足部护理靶向泡足液，包括细胞修护溶液和祛脚气溶液，所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁1％、鱼胶原蛋白肽1％、牛胶原带白肽1％、乳清肽1％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液；所述祛脚气溶液按照重量百分比配制，由水杨酸0.5％、苯甲酸0.5％、硼酸0.5％、鞣酸0.15％、间苯二酚0.1％、呋喃西林0.05％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液。
实施例2
本发明公开的一种祛除脚气足部护理靶向泡足液，包括细胞修护溶液和祛脚气溶液，所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁3％、鱼胶原蛋白肽3％、牛胶原带白肽3％、乳清肽3％,混合配置而成,小分子团活性水补充余量；所述祛脚气溶液按照重量百分比配制，由水杨酸5％、苯甲酸5％、硼酸5％、鞣酸0.5％、间苯二酚0.5％、呋喃西林0.15％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液。
实施例3
本发明公开的一种祛除脚气足部护理靶向泡足液，包括细胞修护溶液和祛脚气溶液，所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁2％、鱼胶原蛋白肽2％、牛胶原带白肽2％、乳清肽2％,混合配置而成,小分子团活性水补充余量；所述祛脚气溶液按照重量百分比配制,由水杨酸3％、苯甲酸3％、硼酸3％、鞣酸3％、间苯二酚0.3％、呋喃西林0.1％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液。
该发明从脚的角质层的表层到皮肤表皮的基底层的清除真菌，渗透到真皮层能真正清除真菌，只清除真菌感染层，修复被感染的皮肤，保护皮肤正常组织，消杀与修护同时进行，小分子团活性水、化合物、肽、镁离子协同作用，彻底祛除各种类型的脚气脚臭、去除角质、抑菌修护、保护足部正常的皮肤组织，短时间内从根本上解决真菌感染问题，达到足部健康的目的。
本具体实施方式的实施例均为本发明的较佳实施例，并非依此限制本发明的保护范围，故：凡依本发明的结构、形状、原理所做的等效变化，均应涵盖于本发明的保护范围之内。
Claims (4)
1.一种祛除脚气足部护理靶向泡足液，包括细胞修护溶液和祛脚气溶液,其特征在于：所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁1～3％、鱼胶原蛋白肽1～3％、牛胶原带白肽1～3％、乳清肽1～3％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液；
所述祛脚气溶液按照重量百分比配制,由水杨酸0.5～5％、苯甲酸0.5～5％、硼酸0.5～5％、鞣酸0.15～0.5％、间苯二酚0.1～0.5％、呋喃西林0.05～0.15％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液。
2.根据权利要求1所述的一种祛除脚气足部护理靶向泡足液，其特征在于：所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁1％、鱼胶原蛋白肽1％、牛胶原带白肽1％、乳清肽1％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液；所述祛脚气溶液按照重量百分比配制,由水杨酸0.5％、苯甲酸0.5％、硼酸0.5％、鞣酸0.15％、间苯二酚0.1％、呋喃西林0.05％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液。
3.根据权利要求1所述的一种祛除脚气足部护理靶向泡足液，其特征在于：所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁3％、鱼胶原蛋白肽3％、牛胶原带白肽3％、乳清肽3％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液；所述祛脚气溶液按照重量百分比配制,由水杨酸5％、苯甲酸5％、硼酸5％、鞣酸0.5％、间苯二酚0.5％、呋喃西林0.15％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液。
4.根据权利要求1所述的一种祛除脚气足部护理靶向泡足液，其特征在于：所述细胞修护溶液按照重量百分比配制,由海洋深层离子镁2％、鱼胶原蛋白肽2％、牛胶原带白肽2％、乳清肽2％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液；所述祛脚气溶液按照重量百分比配制,由水杨酸3％、苯甲酸3％、硼酸3％、鞣酸3％、间苯二酚0.3％、呋喃西林0.1％,混合配置而成,小分子团活性水补充余量对以上溶质进行溶解后成溶液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111236658.9A CN113813285A (zh) | 2021-10-23 | 2021-10-23 | 一种祛除脚气足部护理靶向泡足液 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111236658.9A CN113813285A (zh) | 2021-10-23 | 2021-10-23 | 一种祛除脚气足部护理靶向泡足液 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113813285A true CN113813285A (zh) | 2021-12-21 |
Family
ID=78918860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111236658.9A Pending CN113813285A (zh) | 2021-10-23 | 2021-10-23 | 一种祛除脚气足部护理靶向泡足液 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113813285A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832765A (zh) * | 2016-05-12 | 2016-08-10 | 段泽恺 | 一种防治脚气的外用药液及其制备方法 |
-
2021
- 2021-10-23 CN CN202111236658.9A patent/CN113813285A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832765A (zh) * | 2016-05-12 | 2016-08-10 | 段泽恺 | 一种防治脚气的外用药液及其制备方法 |
Non-Patent Citations (5)
| Title |
|---|
| 包卫洋等: "《海洋生物活性肽的研究与产业化》", 31 December 2020 * |
| 吕霞霞: "《实用临床医学基础与进展》", 31 March 2019 * |
| 张和平等: "《现代乳品工业手册》", 31 August 2005 * |
| 曾庆双: "《中国白酒文化》", 31 August 2013 * |
| 王正国主编: "《创伤学.基础与临床 下》", 31 October 2006 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015176558A1 (zh) | 一种天然维生素c和鱼鳞胶原蛋白肽的组合物及其制备方法 | |
| CN104971200A (zh) | 一种鞣酸ph稳定型痔疮凝胶及其制备方法 | |
| US20100284951A1 (en) | Novel compositions for the treatment of wounds and skin care | |
| CN104307032A (zh) | 一种止痛、抗菌、止血并促进伤口愈合的液体敷料 | |
| CN109646712B (zh) | 一种胶态硫液体敷料及其制备方法 | |
| CN111514161B (zh) | 一种抗口腔溃疡制剂及其应用 | |
| CN113813285A (zh) | 一种祛除脚气足部护理靶向泡足液 | |
| CN111407789A (zh) | 一种泡沫型日常预防治动物蹄浴液及其制备方法与应用 | |
| CN108066401A (zh) | 一种用于治疗鼻炎的药物 | |
| JPS62181219A (ja) | 褥瘡治療剤 | |
| CN1864729A (zh) | 一种纯中药外伤消敛药物 | |
| CN101972360B (zh) | 一种治疗烧烫伤的药物 | |
| CN110946816A (zh) | 天然草本除溃疡清口气口腔喷剂 | |
| CN111000871A (zh) | 一种口腔喷剂及其制备方法 | |
| US6932966B1 (en) | Topically applied reconstituted ocean water mixture and method of producing and using the mixture | |
| CA1313142C (en) | Therapeutic hypertonic seawater solution | |
| CN109846847B (zh) | 一种用于治疗动物皮肤病的泡腾片及其制备方法 | |
| CN101716337A (zh) | 一种治疗脚气、脚癣的药液 | |
| CN107096017A (zh) | 治疗皮肤病的外用中药组合物及其使用方法 | |
| CN114712482B (zh) | 一种含虾青素的洁阴抑菌凝胶及其制备方法 | |
| CN112587603B (zh) | 一种修复外伤创口的中药组合物、创口液及其制备方法 | |
| CN115252883A (zh) | 一种对体表损伤快速修复和灭菌的复合液体敷料配方 | |
| CN1061883C (zh) | 化栓通脉药 | |
| RU2306939C1 (ru) | Способ лечения фурункулеза | |
| CA2299205A1 (en) | Super-oxygenated water solutions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211221 |
|
| RJ01 | Rejection of invention patent application after publication |